Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Herein, we review the epitope approach to vaccine development, and discuss how knowledge of HLA supertypes might be used as a tool in the development of such vaccines. After reviewing the main structural features of the A2-, A3-, B7-, and B44- supertype alleles, and biological data demonstrating their immunological relevance, we analyze the frequency at which these supertype alleles are expressed in various ethnicities and discuss the relevance of those observations to vaccine development. Next, the existence of five new supertypes (A1, A24, B27, B58, and B62) is reported. As a result, it is possible to account for the predominance of all known HLA class I with only nine main functional binding specificities. The practical implications of this finding, as well as its relevance to understanding the functional implication of MHC polymorphism in humans, are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Individual HLA-I alleles are classified into 12 discrete supertypes (52, 53), on the basis of similar peptide-anchor–binding specificities (26, 52, 53).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [52]
In the citing paper
“These supertypes together cover most HLA-A and HLA-B alleles found in distinct populations (52, 53).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [52]
Citations
Cites
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411 · cited 5×
“Independent observations demonstrate that the motif of the mouse class I allele L is identical to the B7-supermotif (Corr et al. 1992; Falk et al. 1991) While the necessary task of fully exploring and cataloging MHC polymorphism continues, we have begun to appreciate the common denominators and similarities hidden wit…”
BackgroundInfluentialRosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
MHC ligands and peptide motifs: first listing
Rammensee, H.-G., Friede, T., & Stevanović, S. (1995) · Immunogenetics · doi:10.1007/bf00172063 · Cited by 1,638
Borrow, P., Lewicki, H., Wei, X., Horwitz, M. S., Peffer, N., Meyers, H., Nelson, J. A., Gairin, J. E., Hahn, B. H., Oldstone, M. B. A., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-205 · Cited by 1,183 · cited 4×
“…also allows focusing of immune responses against multiple conserved epitopes, a factor of crucial importance in the case of rapidly mutating pathogens, such as HIV and HCV (Borrow et al. 1997; Cooper et al. 1999; Goulder et al. 1997a, b; Nowak et al. 1995; Price et al. 1997; Weiner et al. 1995).”
BackgroundInfluentialGoulder, P. J. R., Phillips, R. E., Colbert, R. A., McAdam, S., Ogg, G., Nowak, M. A., Giangrande, P., Luzzi, G., Morgana, B., Edwards, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-212 · Cited by 1,116 · cited 1×
“…also allows focusing of immune responses against multiple conserved epitopes, a factor of crucial importance in the case of rapidly mutating pathogens, such as HIV and HCV (Borrow et al. 1997; Cooper et al. 1999; Goulder et al. 1997a, b; Nowak et al. 1995; Price et al. 1997; Weiner et al. 1995).”
BackgroundRefined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution
Saper, M. A., Bjorkman, P. J., & Wiley, D. C. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90567-p · Cited by 1,077 · cited 2×
“X-ray crystallographic analysis of MHC-peptide complexes revealed allele specific pockets within the peptide binding cleft of MHC molecules which accommodate specific peptide side chains (Fremont et al. 1992; Guo et al. 1992; Madden et al. 1992; Matsumura et al. 1992; Saper et al. 1991).”
BackgroundMethodThe Biochemistry and Cell Biology of Antigen Processing and Presentation
Germain, R. (1993) · Annual Review of Immunology · doi:10.1146/annurev.immunol.11.1.403 · Cited by 1,020 · cited 1×
“The complex of a major histocompatibilty complex (MHC) molecule and a peptidic antigen acts as the ligand recognized by MHC-restricted T cells (Garcia et al. 1999; Germain and Margulies 1993; Yewdell and Bennink 1999).”
BackgroundCrystal Structures of Two Viral Peptides in Complex with Murine MHC Class I H-2K b
Fremont, D. H., Matsumura, M., Stura, E. A., Peterson, P. A., & Wilson, L. A. (1992) · Science · doi:10.1126/science.1323877 · Cited by 861 · cited 1×
“X-ray crystallographic analysis of MHC-peptide complexes revealed allele specific pockets within the peptide binding cleft of MHC molecules which accommodate specific peptide side chains ( Fremont et al. 1992; Guo et al. 1992; Madden et al. 1992; Matsumura et al. 1992; Saper et al. 1991).”
BackgroundSette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J. M., Oseroff, C., Yuan, L., Ruppert, J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.12.5586 · Cited by 830 · cited 1×
“…peptide-MHC binding have also been established (Engelhard 1994; Joyce and Natheson 1994; Sette and Grey 1992; Sidney et al. 1998), and the threshold of affinity associated with generation of immune responses has also been elucidated (Schaeffer et al. 1989; Sette et al. 1994; Southwood et al. 1998).”
BackgroundSelf-citationIdentification of self peptides bound to purified HLA-B27
Jardetzky, T. S., Lane, W. S., Robinson, R. A., Madden, D. R., & Wiley, D. C. (1991) · Nature · doi:10.1038/353326a0 · Cited by 827 · cited 5×
“Pool sequencing motifs for peptides bound to HLAB*1401-02, B*1503, B*1509, B*1510, B*1518, B*380102, B*3901, B*3902, B*3903-04, B*4801-02, B*7301, and B*2701-08 (Barber et al. 1996a, 1997; Boisgérault et al. 1996; DiBrino et al. 1994b; Falk et al. 1995c; Rötzschke et al. 1994; Garcia et al. 1997; Jardetzky et al. 1991…”
BackgroundInfluential
Cited by
Items 101–200 of 636
Development of a novel clustering tool for linear peptide sequences
Dhanda, S. K., Vaughan, K., Schulten, V., Grifoni, A., Weiskopf, D., Sidney, J., Peters, B., & Sette, A. (2018) · Immunology · doi:10.1111/imm.12984 · Cited by 92
Self-citationA systematic bioinformatics approach for selection of epitope-based vaccine targets
Khan, A. M., Miotto, O., Heiny, A. T., Salmon, J., Srinivasan, K. N., Nascimento, E. J. M., Marques, E. T. A., Brusić, V., Tan, T. W., & August, J. T. (2006) · Cellular Immunology · doi:10.1016/j.cellimm.2007.02.005 · Cited by 90
“Thus, it is advantageous to select promiscuous T-cell epitopes that bind to several alleles of HLA supertypes for maximal population coverage [13].”
BackgroundHerd, K., Mahalingam, S., Mackay, I. M., Nissen, M. D., Sloots, T. P., & Tindle, R. W. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.2034-2044.2006 · Cited by 94
“A similar situation in humans would engender optimism that a vaccine comprising CTL epitopes restricted through the major HLA class I supertypes (44) would offer protection to most of the population against most hMPV types.”
BackgroundLeslie, A. J., Price, D. A., Mkhize, P. P., Bishop, K., Rathod, A., Day, C. L., Crawford, H., Honeyborne, I., Asher, T. E., Luzzi, G. A., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4699 · Cited by 89
“an average population coverage of 99%, irrespective of ethnicity (8).”
BackgroundPrinz, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00954 · Cited by 100
“Due to the diverse acceptor sites, different HLA molecules select different peptide repertoires for presentation (37, 38), although the binding specificities may overlap (39, 40).”
BackgroundMacDonald, K. S., Embree, J. E., Nagelkerke, N. J. D., Castillo, J., Ramhadin, S., Njenga, S., Oyug, J., Ndinya‐Achola, J. O., Barber, B. H., Bwayo, J. J., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/318092 · Cited by 88
“This has prompted the hypothesis of convergent evolution in response to infectious disease pressure [13].”
BackgroundStructure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses
Nathan, A., Rossin, E. J., Kaseke, C., Park, R. J., Khatri, A., Koundakjian, D., Urbach, J. M., Singh, N. K., Bashirova, A., Tano-Menka, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.029 · Cited by 87
“We then applied the NetMHCpan 4.1 epitope prediction algorithm (http://www.cbs.dtu.dk/services/NetMHCpan/) to define putative binders for 18 HLA class I alleles that provide >99% Cell 184, 4401–4413, August 19, 2021 4405 ll Article coverage of the global population (A*0101, A*0201, A*0301, A*2402, B*0702, B*0801, B*14…”
InfluentialShams, H., Klucar, P., Weis, S. E., Lalvani, A., Moonan, P. K., Safi, H., Wizel, B., Ewer, K., Nepom, G. T., Lewinsohn, D. M., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.1966 · Cited by 95
“HLA-A*02 is part of the HLA-A2 supertype, which is expressed by 39–46% of Caucasians, North American Blacks, Hispanics, and Asians (50).”
BackgroundQuantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS
Scherer, A., Frater, J., Oxenius, A., Agudelo, J., Price, D. A., Günthard, H. F., Barnardo, M., Perrin, L. H., Hirschel, B. J., Phillips, R. E., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404091101 · Cited by 85
Ojha, R., Pareek, A., Pandey, R. K., Prusty, D., & Prajapati, V. K. (2019) · ACS Omega · doi:10.1021/acsomega.9b00944 · Cited by 84
An overview of in silico vaccine design against different pathogens and cancer
Kardani, K., Bolhassani, A., & Namvar, A. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1794832 · Cited by 96
“The aim of this assessment is predicting the peptides which have a high affinity to bind specific MHC molecules [85].”
BackgroundQuantitating T Cell Cross-Reactivity for Unrelated Peptide Antigens
Ishizuka, J. J., Grebe, K. M., Shenderov, E., Peters, B., Chen, Q., Peng, Y., Wang, L., Dong, T., Pasquetto, V., Oseroff, C., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901607 · Cited by 84
“Peptides predicted to bind MHC class I (H2-K, H2-D, or HLA-A2) were identified from the predicted open reading frames (ORFs) of pathogen sequences using a previously described algorithm (9, 10).”
MethodSelf-citationLoffredo, J. T., Sidney, J., Wojewoda, C. M., Dodds, E. J., Reynolds, M. R., Napoé, G. S., Mothé, B. R., O’Connor, D. H., Wilson, N. A., Watkins, D. I., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.5064 · Cited by 84
“Interestingly, the peptide-binding motif of Mamu-A*02 is similar to that of alleles in the HLA A1 supertype (77).”
BackgroundSelf-citationDing, F., Wang, F., Lu, Y., Li, K., Wang, K.-H., He, X., & Sun, S. (2009) · Hepatology · doi:10.1002/hep.22816 · Cited by 82
“HBc(1-144)-multiepitope did not form core-like particles, as demonstrated by negative staining under electron microscopy, while another fusion protein, HBc(1-78)-multiepitope-HBc(79-144), readily assembled to high and comparable particle concentrations (Fig.”
BackgroundMethodInfluentialMahapatra, S. R., Sahoo, S., Dehury, B., Raina, V., Patro, S., Misra, N., & Suar, M. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1811091 · Cited by 82
“Therefore, population coverage analysis is crucial for design of applicable epitope-based subunit vaccines that bind to several alleles of HLA supertypes [59].”
BackgroundThe contribution of HLA class I antigens in immune status following two doses of rubella vaccination
Ovsyannikova, I. G., Jacobson, R. M., Vierkant, R. A., Jacobsen, S. J., Pankratz, V. S., & Poland, G. A. (2004) · Human Immunology · doi:10.1016/j.humimm.2004.07.001 · Cited by 81
Epitope prediction and identification—Adaptive T cell responses in humans
Sidney, J., Peters, B., & Sette, A. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101418 · Cited by 81
“The alternative strategy is to define epitopes restricted by specific HLA alleles, thus allowing to project coverage in different populations, and ensuring adequate coverage in different ethnicities if the most common alleles [86, 88] expressed in populations worldwide are selected.”
BackgroundSelf-citationAlvarez, M., Postan, M., Weatherly, D. B., Albareda, M. C., Sidney, J., Sette, A., Olivera, G. C., Armenti, A., Tarleton, R. L., & Laucella, S. A. (2008) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000288 · Cited by 80
“95 of a human population, irrespective of ethnicity [26,27].”
BackgroundResultInfluentialSelf-citationKobayashi, H., Song, Y., Hoon, D. S. �., Appella, E., & Celis, E. (2001) · PubMed · Cited by 87
HIV-1 diversity versus HLA class I polymorphism
Stephens, H. A. F. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.11.001 · Cited by 94
T cell response to Hu-D peptides in patients with anti-Hu syndrome
Rousseau, A., Benyahia, B., Dalmau, J. O., Connan, F., Guillet, J., Delattre, J., & Choppin, J. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-1723-1 · Cited by 79
Schwensow, N., Fietz, J., Dausmann, K. H., & Sommer, S. (2007) · Evolutionary Ecology · doi:10.1007/s10682-007-9186-4 · Cited by 84
“With respect to MHC class II DRB alleles, it was primarily developed in the context of vaccine design since supertypes comprise alleles with similar binding properties (Sette and Sidney 1999).”
Tan, T. G., Mui, E. J., Cong, H., Witola, W. H., Montpetit, A., Muench, S. P., Sidney, J., Alexander, J., Sette, A., Grigg, M. E., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.028 · Cited by 83
Self-citationMcMurry, J. A., Gregory, S. H., Moise, L., Rivera, D. S., Buus, S., & Groot, A. S. D. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.039 · Cited by 78
Frahm, N., Adams, S. D., Kiepiela, P., Linde, C., Hewitt, H. S., Lichterfeld, M. D., Sango, K., Brown, N. V., Pae, E., Wurcel, A. G., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10218-10225.2005 · Cited by 77
Identification of non-mutated neoantigens presented by TAP-deficient tumors
Marijt, K. A., Blijleven, L., Verdegaal, E. M. E., Kester, M. G. D., Kowalewski, D. J., Rammensee, H., Stevanović, S., Heemskerk, M. H. M., van der Burg, S. H., & van Hall, T. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180577 · Cited by 80
Therapeutic Vaccine Strategies against Human Papillomavirus
Khallouf, H., Grabowska, A. K., & Riemer, A. B. (2014) · Vaccines · doi:10.3390/vaccines2020422 · Cited by 82
de Alwis, R., Bangs, D. J., Angelo, M. A., Cerpas, C., Fernando, A. N., Sidney, J., Peters, B., Gresh, L., Balmaseda, Á., Silva, A. D. D., et al. (2016) · Journal of Virology · doi:10.1128/jvi.02892-15 · Cited by 85
Self-citationBethune, M. T., Li, X., Yu, J., McLaughlin, J., Cheng, D., Mathis, C., Moreno, B. H., Woods, K., Knights, A. J., García-Díaz, Á., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810653115 · Cited by 75
“Over 80% of people across ethnic groups express at least one allele from three MHCI supertypes (A2, A3, and B7, two of which were represented here) and >99% of people express at least one allele from nine MHCI supertypes (49).”
BackgroundAsymptomatic Human CD4+Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B
Chentoufi, A. A., Binder, N. R., Berka, N., Durand, G., Nguyen, A., Bettahi, I., Maillère, B., & BenMohamed, L. (2008) · Journal of Virology · doi:10.1128/jvi.00692-08 · Cited by 72
“Thus, an effective vaccine could include multiple “asymptomatic” T-cell epitopes present in diverse herpesvirus protein Ags, chosen to represent at least the HLA-DR supertypes, known to provide recognition in up to 95% of the global population, regardless of race and ethnicity (2, 4, 6, 56).”
Oseroff, C., Peters, B., Pasquetto, V., Moutaftsi, M., Sidney, J., Panchanathan, V., Tscharke, D. C., Maillère, B., Grey, H. M., & Sette, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7193 · Cited by 71
“The D1R Ag particularly stands out, being recognized more than once in the context of two MHC restriction elements (H-2K and HLA-B7) and broadly in the context of four HLA supertypes (29) (A01, A03, B07, and B44) and three murine MHC alleles (H-2K, D, and K).”
BackgroundSelf-citationHLA Peptide Length Preferences Control CD8+ T Cell Responses
Rist, M. J., Theodossis, A., Croft, N. P., Neller, M. A., Welland, A., Chen, Z., Sullivan, L. C., Burrows, J. M., Miles, J. J., Brennan, R. M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300292 · Cited by 71
Hasan, A., Hossain, M., & Alam, J. (2013) · Bioinformatics and Biology Insights · doi:10.4137/bbi.s13402 · Cited by 75
Aran, A., Garrigós, L., Curigliano, G., Cortés, J., & Martí, M. (2022) · Cancers · doi:10.3390/cancers14071771 · Cited by 81
“The loss of distinct amino acids in some positions could produce the opposite effect as certain HLA pockets are highly restricted to specific amino acids [64,65].”
BackgroundOvsyannikova, I. G., Jacobson, R. M., Vierkant, R. A., Pankratz, V. S., & Poland, G. A. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.020 · Cited by 70
“Sidney et al. [27] noted that “HLA binding superypes and supermotifs demonstrate that MHC polymorphism ay be functionally more limited than generally thought”. n the case of class II HLA molecules, 50–80% of comon alleles can be classified in a single DR supertype, epending on the ethnicities considered [6].”
BackgroundInfluentialHost–parasite network structure is associated with community-level immunogenetic diversity
Pilosof, S., Fortuna, M. A., Cosson, J., Galan, M., Kittipong, C., Ribas, A., Segal, E., Krasnov, B. R., Morand, S., & Bascompte, J. (2014) · Nature Communications · doi:10.1038/ncomms6172 · Cited by 75
Tumor‐associated carbohydrate antigens: A possible avenue for cancer prevention
Xu, Y., Sette, A., Sidney, J., Gendler, S. J., & Franco, A. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01347.x · Cited by 79
“Glycopeptides can be designed to bind multiple class I MHC alleles To transfer the TACA-containing glycopeptide vaccine strategy from mice to humans, we designed Tn-containing glycopeptides that are potentially capable of binding multiple HLA class I allele”
BackgroundSelf-citationChallenges in the Development of Effective Peptide Vaccines for Cancer
Buteau, C., Markovic, S. N., & Celis, E. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.4.339 · Cited by 71
Sidney, J., Steen, A., Moore, C., Ngo, S., Chung, J., Peters, B., & Sette, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001006 · Cited by 70
Self-citationLazaryan, A., Lobashevsky, E. S., Mulenga, J., Karita, E., Allen, S. A., Tang, J., & Kaslow, R. A. (2006) · Journal of Virology · doi:10.1128/jvi.02119-05 · Cited by 67
“Initially proposed in the late 1990s, four HLA-A and five HLA-B supertype categories encompass the majority of known HLA class I alleles (24, 25).”
BackgroundIn silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes
Moise, L., McMurry, J. A., Buus, S., Frey, S. E., Martin, W. D., & Groot, A. S. D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.018 · Cited by 66
Identification of Protective Lassa Virus Epitopes That Are Restricted by HLA-A2
Botten, J., Alexander, J., Pasquetto, V., Sidney, J., Barrowman, P., Ting, J. P., Peters, B., Southwood, S., Stewart, B. S., Rodriguez‐Carreno, M. P., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00896-06 · Cited by 65
“A second advantage is that broad population coverage (greater than 99%) can be established, providing that epitopes corresponding to multiple HLA supertype families are incorporated into the vaccine (31, 32).”
BackgroundSelf-citationUtilization of genomic sequence information to develop malaria vaccines
Doolan, D. L., Aguiar, J. C., Weiss, W. R., Sette, A., Felgner, P. L., Regis, D. P., Quinones-Casas, P., Yates, J. R., Blair, P. L., Richie, T. L., et al. (2003) · Journal of Experimental Biology · doi:10.1242/jeb.00615 · Cited by 75
Self-citationZhang, G., DeLuca, D. S., Keskin, D. B., Chitkushev, L. T., Zlateva, T., Lund, O., Reinherz, E. L., & Brusić, V. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.11.009 · Cited by 65
“Themajority of HLA class I alleles cluster into nine HLA class I supertypes, A1, A2, A3, A24, B7, B27, B44, B58, and B62, largely based on their overlapping peptide binding repertoires and consensus structures in the main peptide binding pockets (Sette and Sidney, 1999).”
BackgroundInfluentialThe validity of predicted T-cell epitopes
Lundegaard, C., Nielsen, M., & Lund, O. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.10.001 · Cited by 64
Rapin, N., Hoof, I., Lund, O., & Nielsen, M. (2008) · Immunogenetics · doi:10.1007/s00251-008-0330-2 · Cited by 64
“However, many MHC alleles share a large fraction of their peptide-binding repertoire, and it is often possible to find promiscuous peptides, which bind to a set of different alleles (Lund et al. 2004; Sette and Sidney 1999).”
Pérez, C. L., Larsen, M. V., Gustafsson, R. K. L., Norström, M. M., Atlas, A., Nixon, D. F., Nielsen, M., Lund, O., & Karlsson, A. C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.5092 · Cited by 63
“The HLA system is extremely polymorphic, and has a diverse distribution among different ethnic groups (8).”
BackgroundNew concepts in herpes simplex virus vaccine development: notes from the battlefield
Dasgupta, G., Chentoufi, A. A., Nesburn, A. B., Wechsler, S. L., & BenMohamed, L. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.60 · Cited by 64
SARS CTL vaccine candidates; HLA supertype‐, genome‐wide scanning and biochemical validation
Sylvester‐Hvid, C., Nielsen, M., Lamberth, K., Røder, G., Justesen, S. F. L., Lundegaard, C., Worning, P., Thomadsen, H., Lund, O., Brunak, S., et al. (2004) · Tissue Antigens · doi:10.1111/j.0001-2815.2004.00221.x · Cited by 62
“major human populations can be covered with three to nine ‘‘HLA supertypes’’, where the different members of each supertype bind similar peptides (3).”
BackgroundIn silicogrouping of peptide/HLA class I complexes using structural interaction characteristics
Tong, J. C., Tan, T. W., & Ranganathan, S. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl563 · Cited by 64
“Three main clusters are observed: A-I (A 0101), A-II (A 0201) and A-III (A 6801), which are consistent with the assignments of from the groups of Sette (Sette and Sidney, 1999) and Flower (Doytchinova et al., 2004).”
BackgroundMethodInfluentialThe Human Immunopeptidome Project, a Suggestion for yet another Postgenome Next Big Thing
Admon, A., & Bassani‐Sternberg, M. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o111.011833 · Cited by 66
Ojha, R., Gupta, N., Naik, B., Singh, S., Verma, V. K., Prusty, D., & Prajapati, V. K. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105375 · Cited by 63
“With the help of literature survey, we came across that the supertypes A2, A3 and B7 together covers around 88% population globally (Sette and Sidney, 1999; Shen et al., 2018).”
Autoimmune aspects of psoriasis: Heritability and autoantigens
Prinz, J. C. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.011 · Cited by 71
Tang, J., Shao, W., Dorak, M. T., Li, Y., Miike, R., Lobashevsky, E. S., Wiencke, J. K., Wrensch, M., Kaslow, R. A., & Cobbs, C. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0136 · Cited by 61
Dikhit, M. R., Ansari, M. Y., Vijaymahantesh, Kalyani, K., Mansuri, R., Sahoo, B. R., Dehury, B., Amit, A., Topno, R. K., Sahoo, G. C., et al. (2016) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2016.08.037 · Cited by 62
“HLA-A1, -A2, -A3, -A24, -B7, -B44, and -B58) account for an optimal coverage in the human population (N98%) independent of ethnicity (Rammensee et al., 1995; Sette and Sidney, 1999).”
BackgroundLiu, C., Carrington, M. N., Kaslow, R. A., Gao, X., Rinaldo, C. R., Jacobson, L. P., Margolick, J. B., Phair, J., O’Brien, S. J., & Detels, R. (2003) · The Journal of Infectious Diseases · doi:10.1086/374394 · Cited by 66
Definition of MHC Supertypes Through Clustering of MHC Peptide-Binding Repertoires
Reche, P. A., & Reinherz, E. L. (2007) · Methods in molecular biology · doi:10.1007/978-1-60327-118-9_11 · Cited by 64
Gorse, G. J., Baden, L. R., Wecker, M. T., Newman, M. J., Ferrari, G., Weinhold, K. J., Livingston, B. D., Villafana, T. L., Li, H., Noonan, E. A., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.10.061 · Cited by 59
Classification of Human Leukocyte Antigen (HLA) Supertypes
Wang, M., & Claësson, M. H. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1115-8_17 · Cited by 69
Defining the HLA class I‐associated viral antigen repertoire from HIV‐1‐infected human cells
Ternette, N., Yang, H., Partridge, T., Llano, A., Cedeño, S., Fischer, R., Charles, P. D., Dudek, N. L., Mothe, B., Crespo, M., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201545890 · Cited by 58
Cross-reactive human B cell and T cell epitopes between influenza A and B viruses
Terajima, M., Babon, J. A. B., Co, M. D. T., & Ennis, F. A. (2013) · Virology Journal · doi:10.1186/1743-422x-10-244 · Cited by 57
“Most of the CD8 T cell epitopes are restricted by HLA-A1, -A2, -A3 or A24 supertypes [58] and the two CD4 T cell epitopes are restricted by HLA-DR supertype [59] suggesting that these CD8 and CD4 T cell epitopes are expected to be recognized by a majority of human population.”
BackgroundSchanen, B. C., Groot, A. S. D., Moise, L., Ardito, M. T., McClaine, E. M., Martin, W. D., Wittman, V., Warren, W. L., & Drake, D. R. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.02.019 · Cited by 56
Matthews, P. C., Adland, E., Listgarten, J., Leslie, A. J., Mkhwanazi, N. P., Carlson, J. M., Harndahl, M. N., Stryhn, A., Payne, R., Ogwu, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003711 · Cited by 63
“HLA-A*0101 preferentially binds epitopes bearing a small aliphatic residue, such as Thr/Ser/Ile/Met, at position 2 (33, 37, 38), but differs from the HLA-A*7401 allele by expressing a Met residue at position 67 of the molecule.”
BackgroundConserved MHC Class I Peptide Binding Motif Between Humans and Rhesus Macaques
Dzuris, J. L., Sidney, J., Appella, E., Chesnut, R. W., Watkins, D. I., & Sette, A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.283 · Cited by 56
“Such a motif is not found in either human HLA alleles (16) or rhesus macaque class I alleles with a preference for hydrophobic or aromatic residues at the C termini of their ligands (Table IV).”
BackgroundResultSelf-citationTang, J., & Kaslow, R. A. (2003) · AIDS · doi:10.1097/00002030-200317004-00006 · Cited by 62
“based on their shared peptide binding motifs [72,73].”
BackgroundIdentification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1
Asemissen, A. M., Keilholz, U., Tenzer, S., Müller, M., Walter, S., Stevanović, S., Schild, H., Letsch, A., Thiel, E., Rammensee, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1337 · Cited by 55
HLA class I allele promiscuity revisited
Rao, X., Hoof, I., Costa, A. I. C. A. F., van Baarle, D., & Keşmir, C. (2011) · Immunogenetics · doi:10.1007/s00251-011-0552-6 · Cited by 60
“HLA class I molecules may be grouped into several supertypes based on their potential binding motif similarity (Sette and Sidney 1999; Lund et al. 2004; Doytchinova et al. 2004; Kangueane et al. 2005; Reche and Reinherz 2007; Hertz and Yanover 2007; Sidney et al. 2008).”
BackgroundMolero-Abraham, M., Lafuente, E. M., Flower, D. R., & Reche, P. A. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/601943 · Cited by 54
“This is not surprising as these epitopes seem to target 3 mayor supertypes: A2, A3, and B7 [50–52].”
BackgroundRomán, R. G., Jensen, K. J., Jensen, S. S., Leo‐Hansen, C., Jespersen, S., Te, D., Rodrigues, C. M., Janitzek, C. M., Vinner, L., Katzenstein, T. L., et al. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0076 · Cited by 55
“19,20 We have previously shown that immunization with autologous monocyte-derived dendritic cells (MDDCs) pulsed with peptides representing seven HLA-A2-restricted, subdominant HIV-1 cytotoxic T lymphocyte (CTL) minimal epitopes and three CD4 T helper epitopes elicited previously undetectable T…”
Identifying HLA supertypes by learning distance functions
Hertz, T., & Yanover, C. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btl324 · Cited by 54
Large screen approaches to identify novel malaria vaccine candidates
Davies, D. H., Duffy, P. E., Bodmer, J.-L., Felgner, P. L., & Doolan, D. L. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.059 · Cited by 56
Woo, W.-P., Doan, T., Herd, K., Netter, H. J., & Tindle, R. W. (2006) · Journal of Virology · doi:10.1128/jvi.80.8.3975-3984.2006 · Cited by 53
“The approach of delivering a limited number of MHC-I-restricted epitopes to target multiple diseases in humans by use of HBsAg DNA as a vector is feasible, since (i) at least 15 HBsAg CTL epitopes are candidates for replacement (28, 32, 48); (ii) in general, CTL-mediated pathogen and tumor protection is remarkably par…”
BackgroundNMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes
Becker, J. P., Helm, D., Rettel, M., Stein, F., Hernandez‐Sanchez, A., Urban, K., Gebert, J. F., Kloor, M., Neu‐Yilik, G., Doeberitz, M. V. K., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102389 · Cited by 53
Berthelot, L., Laplaud, D. A., Pettré, S., Ballet, C., Michel, L., Hillion, S., Braudeau, C., Connan, F., Lefrère, F., Wiertlewski, S., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200838023 · Cited by 61
Oyarzún, P., Ellis, J. J., González-Galarza, F. F., Jones, A. R., Middleton, D., Mikael Bodén, A., & Kobe, B. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.01.040 · Cited by 52
Tang, S. T., van Meijgaarden, K. E., Caccamo, N., Guggino, G., Klein, M. R., van Weeren, P. C., Kazi, F., Stryhn, A., Zaigler, A., Şahin, U., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002212 · Cited by 56
“80% of individuals from different ethnic groups (31).”
BackgroundBond, K. B., Sriwanthana, B., Hodge, T. W., Groot, A. S. D., Mastro, T. D., Young, N. L., Promadej, N., Altman, J. D., Limpakarnjanarat, K., & McNicholl, J. M. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/088922201750236988 · Cited by 52
Francisco, R. D. S., Bühler, S., Nunes, J. M., Bitarello, B. D., França, G. S., Meyer, D., & Sanchez‐Mazas, A. (2015) · Immunogenetics · doi:10.1007/s00251-015-0875-9 · Cited by 60
“Supertypes were originally defined by sequencing endogenously bound ligands and searching for motifs shared by alleles that bind similar peptides and by analyzing the three-dimensional structure of the HLA molecules (Sette and Sidney 1999; Sidney et al. 1996, 2008).”
InfluentialLiu, J., Zhang, S., Tan, S., Yi, Y. S., Wu, B., Cao, B., Zhu, F., Wang, C., Wang, H., Qi, J., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01841-12 · Cited by 51
“HLA-A1, -A2, -A3, -A24, -B7, -B27, -B44, -B58, and -B62 (61).”
BackgroundPharmacogenetics of Antiepileptic Drug-Induced Hypersensitivity
Bloch, K. M., Sills, G. J., Pirmohamed, M., & Alfirevic, A. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.65 · Cited by 55
Tan, P., Heiny, A. T., Miotto, O., Salmon, J., Marques, E. T. A., Lemonnier, F. A., & August, J. T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008754 · Cited by 53
“However, the limited population coverage of some HLA alleles may be alleviated by focusing on T cell epitopes recognized by HLA supertypes that bind largely overlapping peptide repertoires on the basis of the specificity for the main anchor positions of the presented peptides [10,11].”
BackgroundChoppin, J., Cohen, W. M., Bianco, A., Briand, J., Connan, F., Dalod, M., & Guillet, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.10.6164 · Cited by 51
Burrows, S. R., Elkington, R., Miles, J. J., Green, K. J., Walker, S., Haryana, S. M., Moss, D. J., Dunckley, H., Burrows, J. M., & Khanna, R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1407 · Cited by 50
“This study has indirectly demonstrated that the AYAQKIFKIL epitope from CMV and the PYLFWLAAI epitope from EBV can bind promiscuously to HLA A*2301 and A*2402, thereby validating at the biological level that these alleles can be grouped together into an A24 supertype as proposed by Sette and Sidney (8).”
BackgroundInfluentialSidney, J., del Guercio, M., Southwood, S., & Sette, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5098 · Cited by 50
Self-citationHuman Leukocyte Antigen Class I Supertypes Influence Susceptibility and Severity of Tuberculosis
Balamurugan, A., Sharma, S. K., & Mehra, N. K. (2004) · The Journal of Infectious Diseases · doi:10.1086/381689 · Cited by 49
“This difficultly has recently been alleviated by the introduction of the supermotif classification of HLA-A and -B molecules into 9 different supertypes on the basis of functional similarities of MHC-peptide interactions during antigen presentation [19].”
BackgroundHost-Specific Adaptation of HIV-1 Subtype B in the Japanese Population
Chikata, T., Carlson, J. M., Tamura, Y., Borghan, M. A., Naruto, T., Hashimoto, M., Murakoshi, H., Le, A. Q., Mallal, S. A., John, M., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00147-14 · Cited by 55
Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome
Tanaka, M., Yoshie, M., Sugie, M., Motizuki, H., Kamakura, K., & Tanaka, K. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00157-0 · Cited by 49
“Nine HLA class I supertypes—A1, A2, A3, A24, B7, B27, B44, B58, and B62—exist based on peptide motif similarity [23].”
BackgroundGenetic variability, molecular evolution, and geographic diversity of HLA-B27
Blanco-Gelaz, M. Á., López‐Vázquez, A., Garcı́a-Fernández, S., Martı́nez-Borra, J., Gonzalez, S. R., & López‐Larrea, C. (2001) · Human Immunology · doi:10.1016/s0198-8859(01)00299-3 · Cited by 49
Staska, L. M., Davies, C. J., Brown, W. C., McGuire, T. C., Suarez, C. E., Park, J. Y., Mathison, B. A., Abbott, J. R., & Baszler, T. V. (2005) · Infection and Immunity · doi:10.1128/iai.73.3.1321-1329.2005 · Cited by 49
“Not all genetically different MHC molecules are functionally different, and for humans, the functional binding specificities of predominant MHC class I molecules fall into nine supertypes (46).”
BackgroundSimultaneous Prediction of Binding Capacity for Multiple Molecules of the HLA B44 Supertype
Sidney, J., Southwood, S., Pasquetto, V., & Sette, A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5964 · Cited by 49
Self-citationMonajemi, M., Woodworth, C. F., Zipperlen, K., Gallant, M., Grant, M. D., & Larijani, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093428 · Cited by 53
Scholzen, A., Richard, G., Moise, L., Baeten, L. A., Reeves, P. M., Martin, W. D., Brauns, T. A., Boyle, C., Paul, S. R., Bucala, R., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00207 · Cited by 52
Sharma, S. K., Balamurugan, A., Pandey, R. M., Saha, P. K., & Mehra, N. K. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0007oc · Cited by 47
“Because the high degree of polymorphism has become a major obstacle for demonstrating the single antigen/allelic association in class I, we classified the HLA-A and -B locus specificities into nine functionally different supertypes as suggested by Sette and Sidney ( 27 ).”
BackgroundSethi, G., Varghese, R. P., Lakra, A. K., Nayak, S. S., Krishna, R., & Hwang, J. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-66858-5 · Cited by 57
“For the epitope forecasting, 3 HLA class I supertypes were assessed: A2, A3, and B7; they present an overall population coverage of 86% 39,40 .”
MethodTerry, F. E., Moise, L., Martin, R., Torres, M., Pilotte, N., Williams, S. A., & Groot, A. S. D. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.955478 · Cited by 46
Wang, G., Wan, H., Jian, X., Li, Y., Ouyang, J., Tan, X., Zhao, Y., Lin, Y., & Xie, L. (2020) · BioMed Research International · doi:10.1155/2020/5798356 · Cited by 52
“With the advances in HLA research, Sette and Sidney [14] classi fi ed, for the fi rst time, overlapping peptide binding repertoires into nine major functional HLA supertypes (A1, A2, A3, A24, B7, B27, B44, B58, and B62).”
Johnson, K. L., Ovsyannikova, I. G., Mason, C. J., Bergen, H. R., & Poland, G. A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.126 · Cited by 47
“The existence of HLA allelic “supertypes” (for example, the HLAA2, A3, B7, and B62 supertypes), which are functionally defined by their ability to bind similar sets of, and in some cases, identical peptides [8-10], allow for the identification of “promiscuous” or shared presented peptides that possess enormous potenti…”
BackgroundKarlsson, I., Brandt, L., Vinner, L., Kromann, I., Andreasen, L. V., Andersen, P. L., Gerstoft, J., Kronborg, G., & Fomsgaard, A. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.12.005 · Cited by 50
Ichihashi, T., Yoshida, R., Sugimoto, C., Takada, A., & Kajino, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024626 · Cited by 45
“HLAA*2402 is one of the major HLA supertypes with approximately 60% of the population in Japan being positive for this specific HLA subtype [28].”
BackgroundMatsueda, S., Takedatsu, H., Yao, A., Tanaka, M., Noguchi, M., Itoh, K., & Harada, M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0682 · Cited by 45
Metadata
- Authors
- Sette, A., & Sidney, J.
- ORCID
- Venue
- Immunogenetics
- Published
- 1999-11
- Volume
- 50
- Issue
- 3-4
- Pages
- 201-212
- ISSN
- 0093-7711 (ISSN-L)
- 1432-1211
- OpenAlex
- W2052321000
- Cited by
- 635
- References
- 115
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 19 · 2023: 18 · 2022: 16 · 2021: 21 · 2020: 25 · 2019: 14 · 2018: 20 · 2017: 19 · 2016: 14 · 2015: 26 · 2014: 26 · 2013: 27 · 2012: 37
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Immunogenetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01ai045241-010, n01ai095362-000)
- National Institute of Allergy and Infectious Diseases (N01 AI-45241, N01-AI-95362)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- HLA-A, HLA-B, MHC polymorphism
- MeSH terms
- Alleles, Amino Acid Sequence, Animals, Epitopes, Humans, Molecular Sequence Data, Polymorphism, Genetic, HLA-A Antigens, HLA-B Antigens, Histocompatibility Antigens Class I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.